Marker Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Marker Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $16.07 million for the year ending 2025.

  • Marker Therapeutics, Inc. showed a decrease of -16.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
  • XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 9 years of available data (2017 to 2025), Marker Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 213.3%.
  • Historical annual values: Fiscal year 2025: $16.07 million | Fiscal year 2024: $19.19 million | Fiscal year 2023: $15.11 million | Fiscal year 2022: $11.78 million | Fiscal year 2021: $42.35 million | Fiscal year 2020: $21.35 million | Fiscal year 2019: $43.90 million | Fiscal year 2018: $61.75 million | Fiscal year 2017: $5.13 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: